Reinhart Partners Has Increased Bok Finl Com New (BOKF) Holding By $3.30 Million; Merrimack Pharmaceuticals (MACK) Shorts Lowered By 0.95%

November 15, 2017 - By Adrian Mccoy

Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK) had a decrease of 0.95% in short interest. MACK’s SI was 1.80 million shares in November as released by FINRA. Its down 0.95% from 1.82M shares previously. With 176,500 avg volume, 10 days are for Merrimack Pharmaceuticals Incorporated (NASDAQ:MACK)’s short sellers to cover MACK’s short positions. It closed at $11.34 lastly. It is down 44.78% since November 15, 2016 and is downtrending. It has underperformed by 61.48% the S&P500.

Reinhart Partners Inc increased Bok Finl Corp Com New (BOKF) stake by 16.76% reported in 2017Q2 SEC filing. Reinhart Partners Inc acquired 39,345 shares as Bok Finl Corp Com New (BOKF)’s stock declined 2.06%. The Reinhart Partners Inc holds 274,135 shares with $23.06M value, up from 234,790 last quarter. Bok Finl Corp Com New now has $5.43B valuation. It closed at $82.91 lastly. It is down 36.84% since November 15, 2016 and is uptrending. It has outperformed by 20.14% the S&P500.

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The company has market cap of $151.20 million. The Firm is engaged in discovering, developing and commercializing medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. It currently has negative earnings. The Firm has one marketed therapeutic oncology product and multiple targeted therapeutic oncology candidates in clinical development.

Investors sentiment increased to 0.88 in 2017 Q2. Its up 0.24, from 0.64 in 2017Q1. It increased, as 19 investors sold Merrimack Pharmaceuticals Inc shares while 29 reduced holdings. 15 funds opened positions while 27 raised stakes. 63.69 million shares or 20.11% less from 79.72 million shares in 2017Q1 were reported. The Minnesota-based Us Bankshares De has invested 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Geode Capital Ltd Liability Co holds 1.00M shares. Tudor Corporation Et Al holds 0% or 37,183 shares. Bancshares reported 0% in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). California State Teachers Retirement reported 0% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Nationwide Fund Advsr reported 71,907 shares stake. Goldman Sachs Group Inc has 910,788 shares for 0% of their portfolio. Proshare Advisors Ltd Liability Corporation holds 0% or 79,312 shares in its portfolio. J Goldman And Ltd Partnership invested in 266,760 shares or 0.02% of the stock. Moreover, Da Davidson has 0% invested in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Great West Life Assurance Can reported 0% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK). Schwab Charles Invest Mngmt holds 0% of its portfolio in Merrimack Pharmaceuticals Inc (NASDAQ:MACK) for 258,877 shares. Rhumbline Advisers invested in 0% or 145,089 shares. Raymond James And Associate stated it has 61,383 shares. Moreover, Alesco Limited Liability Corp has 0% invested in Merrimack Pharmaceuticals Inc (NASDAQ:MACK).

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, August 12 by Oppenheimer. On Friday, August 19 the stock rating was initiated by BTIG Research with “Neutral”. The stock of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) earned “Hold” rating by Robert W. Baird on Monday, September 11. The firm has “Outperform” rating given on Wednesday, August 12 by Mizuho. The stock has “Neutral” rating by JP Morgan on Friday, October 7. Robert W. Baird maintained Merrimack Pharmaceuticals Inc (NASDAQ:MACK) rating on Friday, October 13. Robert W. Baird has “Hold” rating and $15.0 target. Robert W. Baird initiated Merrimack Pharmaceuticals Inc (NASDAQ:MACK) on Friday, May 27 with “Neutral” rating. Mizuho maintained Merrimack Pharmaceuticals Inc (NASDAQ:MACK) on Wednesday, December 23 with “Buy” rating. The stock of Merrimack Pharmaceuticals Inc (NASDAQ:MACK) earned “Outperform” rating by Oppenheimer on Tuesday, October 27. Brean Capital maintained the stock with “Buy” rating in Tuesday, August 11 report.

Investors sentiment decreased to 0.94 in 2017 Q2. Its down 0.41, from 1.35 in 2017Q1. It dropped, as 19 investors sold BOKF shares while 50 reduced holdings. 16 funds opened positions while 49 raised stakes. 20.01 million shares or 3.19% less from 20.67 million shares in 2017Q1 were reported. King Luther Cap Mngmt Corporation holds 51,303 shares or 0.04% of its portfolio. Horizon Kinetics Limited Liability Company, New York-based fund reported 9,779 shares. Geode Capital Mngmt Ltd Liability Co reported 0.01% of its portfolio in BOK Financial Corporation (NASDAQ:BOKF). National Bank Of Ny Mellon Corporation has invested 0% of its portfolio in BOK Financial Corporation (NASDAQ:BOKF). Northwestern Mutual Wealth Mgmt reported 28 shares. Millennium Mngmt Limited Liability Corporation reported 31,356 shares. Manufacturers Life Insurance Company The reported 0.03% of its portfolio in BOK Financial Corporation (NASDAQ:BOKF). Morgan Stanley has 0% invested in BOK Financial Corporation (NASDAQ:BOKF). Lsv Asset Mgmt holds 52,300 shares. Bokf Na holds 0.29% or 109,037 shares. Ameriprise Incorporated reported 5,466 shares. Cadence Limited Liability owns 3,926 shares or 0.02% of their US portfolio. Neuberger Berman Grp Inc Ltd Llc has invested 0.19% in BOK Financial Corporation (NASDAQ:BOKF). Rafferty Asset Mngmt Ltd Company invested 0.01% of its portfolio in BOK Financial Corporation (NASDAQ:BOKF). Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in BOK Financial Corporation (NASDAQ:BOKF).

Among 13 analysts covering BOK Financial (NASDAQ:BOKF), 5 have Buy rating, 0 Sell and 8 Hold. Therefore 38% are positive. BOK Financial has $9500 highest and $55 lowest target. $79.85’s average target is -3.69% below currents $82.91 stock price. BOK Financial had 37 analyst reports since July 30, 2015 according to SRatingsIntel. On Monday, January 9 the stock rating was upgraded by Wells Fargo to “Market Perform”. The firm has “Hold” rating given on Friday, October 27 by Piper Jaffray. Piper Jaffray maintained BOK Financial Corporation (NASDAQ:BOKF) rating on Tuesday, September 12. Piper Jaffray has “Hold” rating and $89.0 target. Macquarie Research downgraded BOK Financial Corporation (NASDAQ:BOKF) on Wednesday, January 13 to “Underperform” rating. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, January 14. The firm earned “Neutral” rating on Friday, October 7 by Wedbush. The company was maintained on Thursday, July 30 by RBC Capital Markets. The stock of BOK Financial Corporation (NASDAQ:BOKF) earned “Neutral” rating by Sterne Agee CRT on Thursday, August 20. RBC Capital Markets maintained BOK Financial Corporation (NASDAQ:BOKF) on Thursday, September 7 with “Hold” rating. The company was maintained on Monday, August 28 by Keefe Bruyette & Woods.

Reinhart Partners Inc decreased Invesco Ltd (NYSE:IVZ) stake by 72,067 shares to 807,864 valued at $28.43 million in 2017Q2. It also reduced Sabre Corp Com (NASDAQ:SABR) stake by 148,500 shares and now owns 1.29M shares. Archer Daniels (NYSE:ADM) was reduced too.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts